Search results
Study: Older Adults With Aggressive Blood Cancer A | Newswise
Newswise· 18 hours agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to ...
Philadelphia jury awards former mechanic $725.5M in Exxon Mobil case
Philly.com· 7 hours agoA Philadelphia jury sided against Exxon Mobil Corp. and awarded $725.5 million on Thursday to a...
Researchers discover new target for potential leukemia therapy
Medical Xpress· 2 days agoThe study provides both mechanistic and preclinical evidence supporting the rapid initiation of...
CD7 expression tied to poorer outcomes with newly diagnosed leukemia
Medical Xpress· 6 days agoCD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid ...
GlycoMimetics downgraded after Phase 3 trial fails to meet endpoint By Investing.com
Investing.com· 3 days ago(NASDAQ:GLYC) stock, moving the biotech firms rating from Buy to Neutral following disappointing...
Earnings call: Kura Oncology reports on ziftomenib's progress By Investing.com
Investing.com· 4 days agoZiftomenib has received Breakthrough Therapy designation from the FDA for the treatment of...
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
NBC 17 Raleigh· 1 day agoMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of...
The Pilot News· 4 days agoDeerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second ...
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
The Grass Valley Union· 3 days agoFirst quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 millionExpanded Rigel's portfolio with acquisition of
Curis to Present Updated Data from the TakeAim Leukemia Study
WPRI Providence· 11 hours agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company ...